Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE
Rhinology Journal · 2023
DOI: 10.4193/rhin22.416 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Rhinology Journal, 2023. Verfasst von J Mullol und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain. Hauptthemen laut MEDLINE: Sinusitis, Antibodies, Monoclonal, Humanized, Nasal Polyps, Rhinitis. Die Arbeit wurde bisher 9-mal zitiert (Crossref).
Abstract (Originalsprache)
BACKGROUND: Loss of smell is one of the most bothersome and difficult-to-treat symptoms in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP). METHODOLOGY: SYNAPSE was a 52-week Phase III study of 4-weekly mepolizumab (100 mg subcutaneously) plus standard of care in adults with severe bilateral CRSwNP. This post hoc analysis assessed changes from baseline to study end in loss of smell visual analogue scale (VAS) symptom score, in patients stratified by several baseline clinical characteristics. SinoNasal Outcomes Test (SNOT)-22 sense of smell/taste item and University of Pennsylvania Smell Identification Test (UPSIT) scores were also assessed. RESULTS: SYNAPSE enrolled 407 patients (mepolizumab=206; placebo=201) with impaired sense of smell at baseline. Improvements from baseline to study end in loss of smell VAS score were greater with mepolizumab versus placebo (treatment difference: −0.37) and most notable in patients with fewer or more recent prior surgeries (treatment difference: 1 vs 2 vs more than 2 prior surgeries,−1.29 vs −0.23 vs −0.07; =3 years since last surgery, −0.89 vs 0.22). Approximately 25% of patients had baseline UPSIT scoresavailable; among those scoring =19 by study end. The SNOT-22 sense of smell/taste item score improved with mepolizumab versus placebo. CONCLUSIONS: Mepolizumab treatment improved patients' perceived sense of smell, as measured by loss of smell VAS score and SNOT-22 sense of smell/taste item score in patients with severe refractory CRSwNP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Catalonia, Spain.
- University College London, London, UK;Royal National Throat Nose and Ear Hospital, UCLH, London, UK.
- Department of Otorhinolaryngology, Dusseldorf University Hospital (UKD), Dusseldorf, Germany.
- Department of Otolaryngology Head and Neck Surgery, Eastern Virginia Medical School, VA, USA.
- Respiratory Patient Centered Outcomes, Value Evidence and Outcomes, GSK, GSK House, Brentford, Middlesex, UK.
- Respiratory Therapeutic Area, GSK, Research Triangle Park, NC, USA.
Zitieren
APA
Mullol, J., Lund, V. J., Wagenmann, M., Han, J. K., Sousa, A. N., Smith, S. G., Mayer, B., Chan, R. H., & Fokkens, W. J. (2023). Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE. Rhinology Journal. https://doi.org/10.4193/rhin22.416
Vancouver
Mullol J, Lund VJ, Wagenmann M, Han JK, Sousa AN, Smith SG, et al. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE. Rhinology Journal. 2023. doi:10.4193/rhin22.416
BibTeX
@article{Mullol2023,
author = {Mullol, J and Lund, V J and Wagenmann, M and Han, J K and Sousa, A N and Smith, S G and Mayer, B and Chan, R H and Fokkens, W J},
title = {Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE},
journal = {Rhinology Journal},
year = {2023},
doi = {10.4193/rhin22.416}
}
EUVIMED